In vitro investigations on the differential pro-oxidant and/or antioxidant properties of cyclosporin A and tacrolimus in human and rat liver microsomes

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 5, 2006, Pages 225-232

  Lupp, Amelie ^a   Kuhn, U D ^a   Karge, E ^a   Adam, G ^a   Fleck, C ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cyclosporin A; Cytochrome P450; Free radicals; Lipid peroxidation; Tacrolimus

Indexed keywords

BETA NAPHTHOFLAVONE; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; HYDROGEN PEROXIDE; LUCIGENIN; LUMINOL; OXIDOREDUCTASE; PHENOBARBITAL; TACROLIMUS;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPID PEROXIDATION; LIVER MICROSOME; MALE; NONHUMAN; RAT;

EID: 33646424361     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44225     Document Type: Article

References (60)

1. Ahmed SS, Strobel HW, Napoli KL, Grevel J. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. J Pharmacol Exp Ther. 1993; 265: 1047-1054.
2. Akgun S, Tekeli A, Isbir SC, Civelek A, Ak K, Sirvanci S, Arbak S, Yaylim I, Arsan S. FK506 to prevent lung injury after hindlimb ischemia and reperfusion in a rat model: an electron microscopic study. Surgery Today. 2004; 34: 678-684.
3. Allen RC. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 1986; 133: 449-491.
4. Andres D, Cascales M. Novel mechanism of vitamin E protection against cyclosporine A cytotoxicity in cultured rat hepatocytes. Biochem Pharmacol. 2003; 64: 267-276.
5. Assis SM, Monteiro JL, Seguro AC. L-arginine and allo-purinol protect against cyclosporine nephrotoxicity. Transplantation. 1997; 63: 1070-1073.
6. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis. 1997; 29: 465-477.
7. Brunner LJ, Bennett WM, Koop DR. Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner. Kidney Int. 1998; 54: 216-223.
8. Buege JKA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52: 302-310.
9. Cantarovich D, Renou M, Megnigbeto A, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Karam G, Soulillou JP. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse effects. Transplantation. 2005; 79: 72-78.
10. Cooney G, Jeevanadam V, Choudhury S, Feutren G, Mueller EA, Eisen HJ. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over one year. Transplantation Proceedings. 1998; 30: 1892-1894.
11. Deters M, Strubelt O, Younes M. Reevaluation of cyclosporine induced hepatotoxicity in the isolated perfused rat liver. Toxicology. 1997; 123: 197-206.
12. Devaraj S, Li DJ, Vazquez M, Jialal I. Cyclosporin A does not increase the oxidative susceptibility of low density lipoprotein in vitro. Free Radic Biol Med. 1999; 26: 1064-1068.
13. Dunn SP, Cooney GF, Kulinsky A, Falkenstein K, Pierson A, Elder CA, Meligeni J. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation. 1995; 60: 1438-1442.
14. Durak I, Kacmaz M, Cimen MY, Buyukkocak S, Elgun S, Öztürk HS. The effects of cyclosporine on antioxidant enzyme activities and malondialdehyde levels in rabbit hepatic tissues. Transplant Immunol. 2002; 10: 255-258.
15. Erguder IB, Cetin R, Devrim E, Kilicoglu B, Avci A, Durak I. Effects of cyclosporine on oxidant/antioxidant status in rat ovary tissues: protective role of black grape extract. Int Immunopharmacol. 2005; 5: 1311-1315.
16. Garcia-Criado FJ, Palma-Vargas JM, Valdunciel-Garcia JJ, Toledo LH, Misawa K, Gomez-Alonso A, Toledo-Pereyra LH. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. Transplantation. 1997; 64: 594-598.
17. Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just a damage. Eur Heart J. 2003; 24: 2161-2163.
18. Haberland A, Henke W, Grime T, Siems W, Jung K, Schimke I. Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment. Inflammation Res. 1997; 46. 452-454.
19. Hagar HH. The protective effect of taurine against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Toxicol Lett. 2004; 151: 335-343.
20. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant. 1999; 13: 209-220.
21. Hildebrandt AG, Roots I, Tjoe M. Hydrogen peroxide in hepatic microsomes. Methods Enzymol. 1978; 52: 342-350.
22. Inselmann G, Barth A, Engemann R, Heidemann HT. Cyclosporin-A-induced lipid peroxidation in human liver microsomes and its influence on cytochrome P-450. Eur J Clin Invest. 1991; 21: 461-465.
23. Jiménez R, Galán AI, González de Buitrago JM, Palamero J, Muñoz ME. Glutathione metabolism in cyclosporine A-treated rats: dose- and time-related changes in liver and kidney. Clin Exp Pharmacol Physiol. 2000; 27: 991-996.
24. Kaymaz M, Emmez H, Bukan N, Dursun A, Kurt G, Pasaoglu A. Effectiveness of FK506 on lipid peroxidation in the spinal cord following experimental traumatic injury. Spinal Cord. 2005; 43: 22-26.
25. Klinger W, Müller D. The influence of age on the protein concentration in serum, liver and kidney of rats determined by various methods. Z Versuchstierk. 1974; 16: 146-153.
26. Krauskopf A, Buetler TM, Nguyen NSD, Macé K, Ruegg UT. Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450. Br J Pharmacol. 2002; 135: 977-986.
27. Kumar KV, Naidu MU, Shifow AA, Prayag A, Ratnakar KS. Melatonin: an antioxidant protects against cyclosporine-induced nephrotoxicity. Transplantation. 1999; 67: 1065-1068.
28. Ladona MG, Spalding DJ, Ekman L, Lindström B, Rane A. Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P450 PCN and interactions with important fetal corticosteroids. Biochem Pharmacol. 1989; 38: 3147-3155.
29. Lake BG, Renwick AB, Cunningham ME, Price RJ, Surry D, Evans DC. Comparison of the effects of some CYP3A and other enzyme inducers on replicative DNA synthesis and cytochrome P450 isoforms in rat liver. Toxicology. 1998; 131: 9-20.
30. Lewis DFV. Cytochromes P450: structure, function and mechanism. London: Taylor & Francis; 1996.
31. Loinaz C, Marin LM, Gonzalez-Pinto I, Gomez R, Jimenez C, Moreno E. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. Transplant Proc. 2001; 33: 3439-3441.
32. Longoni B, Migliori M, Ferretti A, Origlia N, Panichi V, Boggi U, Filippi C, Cuttano MG, Giovannini L, Mosca F. Melatonin prevents cyclosporine-induced nephrotoxicity in isolated and perfused rat kidney. Free Rad Res. 2002; 36: 357-363.
33. Lupp A, Kerst S, Karge E. Evaluation of possible pro- or antioxidant properties and of the interaction capacity with the microsomal cytochrome P450 system of different NMDA-receptor ligands and of taurine in vitro. Exp Toxic Pathol. 2003a; 54: 441-448.
34. Lupp A, Hugenschmidt S, Danz, M, Müller D. Influence of recipient gender on cytochrome P450 isoforms expression in intrasplenic fetal liver tissue transplants in rats. Toxicology. 2003b; 188: 171-186.
35. Lupp A, Kuhn UD, Herwig R, Karge E, Rost M, Scheele J, Fleck C. Cyclosporine A and tacrolimus: in vitro investigations on the differential interactions with the cytochrome P450 system in rat and human liver. Exp Toxic Pathol. 2003c; 54: 467-473.
36. Lupp A, Hugenschmidt S, Rost M, Müller D. Influence of recipient gender on intrasplenic fetal liver tissue transplants in rats: cytochrome P450-mediated monooxygenase functions. Toxicology. 2004; 197: 199-212.
37. Mohamadin AM, El-Beshbishy HA, El-Mahdy MA. Green tea extract attenuates cyclosporine A-induced oxidative stress in rats. Pharmacol Res. 2005; 51: 51-57.
38. Montagnino G, Kramer BK, Arias M, European Tacrolimus vs. Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. Transplant Proc. 2002; 34: 1635-1637.
39. Müller-Peddinghaus R, Wurl M. The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers. Biochem Pharmacol. 1987; 36: 1125-1132.
40. Nguyen NSD, Cottet-Maire F, Buetler TM, LoRusso A, Krauskopf AS, Armstrong JW, Vickers AEM, Macé K, Ruegg UT. Metabolism-dependent stimulation of reactive oxygen species and DNA synthesis by cyclosporin A in rat smooth muscle cells. Free Rad Biol Med. 1999; 27: 1267-1275.
41. Parra T, De Arriba G, Conejo JR, Cantero M, Arribas I, Goni M, Rodriguez-Puyol D, Rodriguez-Puyol M, Carballo F. Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats - effect of vitamin E on cyclosporine nephrotoxicity. Transplantation. 1998; 66: 1325-1329.
42. Prueksaritanont T, Correia MA, Rettie AE, Swinney DC, Thomas DE, Benet LZ. Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochrome P450 3A. Drug Metab Dispos. 1993; 21: 730-737.
43. Rezzani R, Rodella L, Dessy C, Daneau G, Bianchi R, Feron O. Changes in hsp90 expression determine the effects of cyclosporine A on the NO pathway in rat myocardium. FEBS Lett. 2003; 552: 125-129.
44. Rezzani R, Buffoli B, Rodella L, Stacchiotti A, Bianchi R. Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver. Int Immunopharmacol. 2005a; 5: 1397-1405.
45. Rezzani R, Giugno L, Buffoli B, Bonomini F, Bianchi R. The protective effect of caffeic acid phenethyl ester against cyclosporine A-induced cardiotoxicity in rats. Toxicology. 2005b; 212: 155-164.
46. Satyanarayana PS, Singh D, Chopra K. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats. Meth Find Exp Clin Pharmacol. 2001; 23: 175-181.
47. Satyanarayana PS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron. 2002; 92: 685-692.
48. Serino F, Gruvel J, Napoli KL, Kahan BD, Strobel HW. Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition. Mol Cell Biochem. 1993; 122: 101-112.
49. Silman N, Artman M, Engelberg H. Effect of magnesium and spermine on the aggregation of bacterial and mammalian ribosomes. Biochem Biophys Acta. 1965; 103: 231-240.
50. Singh A, Naidu PS, Kulkarni SK. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. Eur J Pharmacol. 2003; 477: 87-94.
51. St. Peter SD, Moss AA, Mulligan DC. Effects of tacrolimus on ischemia-reperfusion injury. Liver Transplant. 2003; 9: 105-116.
52. Suleymanlar G, Suleymanlar I, Shapiro JI, Chan L. Possible role of lipid peroxidation in cyclosporine nephrotoxicity in rats. Transplant Proc. 1994; 26: 2888-2889.
53. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A. N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant. 1999; 14: 923-929.
54. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM, Smart FW, Tolman DE, Frazier OH, Young JB, Van Veldhuisen P. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999; 18: 336-345.
55. Urbizu JW, Zarraga S, Gomez-Ullate P, Amenabar JJ, Gainza FI, Lampreabe I, Virto J, Orbe J. Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine. Transplant Proc. 2003; 35: 1704-1705.
56. Van Hoof JP, Christiaans MH. Use of tacrolimus in renal transplantation. Transplant Proc. 1999; 31: 3298-3299.
57. Varghese Z, Fernando RL, Turakhia G, Psimenou E, Fernando ON, Sweny P, Powis SH, Moorhead JF. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients. Kidney Int. 1999; 71 (Suppl): 137-140.
58. Wolf A, Trendelenburg CF, Diez-Fernandez C, Prieto P, Houy S, Trommer WE, Cordier A. Cyclosporine A-induced oxidative stress in rat hepatocytes. J Pharmacol Exp Ther. 1997; 280: 1328-1334.
59. Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol. 1999; 28: 65-68.
60. Zima T, Kamenikova L, Janebova M, Buchar E, Crkovska J, Tesar V. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail. 1998; 20: 471-479.